ArticleLancet regional health. Americas2025
Prevalence, distribution and future projections of Parkinson disease in Brazil: insights from the ELSI-Brazil cohort study.
Article in Lancet regional health. Americas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Potential Relevance of Amazonian Diet Components in Parkinson's Disease: An Integrative Review with Multivariate Analysis.Nutrients · 2026Review
- Environmental determinants of Parkinson's disease and attributable burden in Latin America.Research square · 2026Article
- Sex difference in Parkinson's disease hospitalization rates in Brazil (2010-2024).BMC neurology · 2026Article
- Levodopa-Induced dyskinesia in Latin America: Prevalence and associated clinical factors in the LARGE-PD cohort.Journal of Parkinson's disease · 2026Article
- Profile and outcomes of Parkinson's disease deep brain stimulation in a public tertiary center in Brazil: retrospective cohort.Arquivos de neuro-psiquiatria · 2026Observational
- Impact of a Public Health Policy on Accessibility to Levodopa for People with Parkinson's Disease in Brazil.Movement disorders clinical practice · 2026Article
- Resveratrol-Loaded Polymeric Nanoparticles Protect Against Rotenone-Induced Parkinsonian-Like Cellular Damage In Vitro: Association with NRF2/HMOX-1 Expression Changes.Neurochemical research · 2026Article
- Bridging global diversity gaps in Parkinson disease research.Nature reviews. Neurology · 2026Review
- North-South asymmetry of Parkinson's disease mortality in Brazil between 2009 and 2023: a spatial analysis.Scientific reports · 2026Article
- An online platform to increase access to gait rehabilitation for underserved Parkinson's disease communities.Journal of Parkinson's disease · 2026Article
- Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review.Current issues in molecular biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: There is limited epidemiological data regarding Parkinson's disease (PD) prevalence in Brazil, which hinders adequate public health policies planning and patient care. This study aimed to investigate the distribution, prevalence, and clinical characteristics of PD among older adults in Brazil. Methods: This cross-sectional study used data from the ELSI-Brazil cohort, a Brazilian nationally representative study of individuals aged 50 and older. Data were collected through door-to-door surveys with standardized questionnaires. PD diagnosis was based on self-reported data. We calculated PD prevalence in the general population and specific age groups, studied its association with clinical variables, and projected PD prevalence in Brazil from 2024 to 2060. Findings: A total of 9881 respondents were included in this study, and 93 reported a medical diagnosis of PD. The crude prevalence of PD among Brazilians aged 50 or more was 0.84% (95% CI: 0.64%-1.09%), with an age- and sex-standardized prevalence of 0.86% (95% CI: 0.62%-1.10%). Men were more affected than women (OR: 2.35, 95% CI: 1.35-4.08; p < 0.01), and the prevalence was higher in older age groups, from 0.39% in those aged 50-59 years to 2.75% in those 80 years and older. PD individuals had higher rates of stroke, depression, functional dependency, and were more likely to need walking support or be bedridden. Projections indicated that PD cases in Brazil will rise from 535,999 (95% CI: 309,963-922,948) in 2024 to 1,250,638 (95% CI: 734,660-2,117,585) by 2060. Interpretation: This study reveals the prevalence and distribution of PD in Brazil, showing many patients with advanced disease and suggesting underdiagnosis in early stages. There is a need for better diagnostic accuracy, improved access to neurologists, and comprehensive public health strategies to manage the rising prevalence and healthcare demands of PD in Brazil. Funding: This study did not receive any funding. The ELSI-Brazil cohort was funded by the Ministry of Health of Brazil.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.